Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S025000, C514S028000, C514S277000, C514S281000, C514S288000, C435S006120, C435S069100, C435S069800, C435S208000, C435S206000, C424S094610
Reexamination Certificate
active
07141582
ABSTRACT:
Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8–12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.
REFERENCES:
patent: 5030638 (1991-07-01), Partis et al.
patent: 5051407 (1991-09-01), Boshegan et al.
patent: 5250545 (1993-10-01), Tsuroka et al.
patent: 5399567 (1995-03-01), Platt et al.
patent: 5561221 (1996-10-01), Yoshida et al.
patent: 5580884 (1996-12-01), Platt et al.
patent: 5656641 (1997-08-01), Platt et al.
patent: 5691306 (1997-11-01), Bergeron et al.
patent: 5786368 (1998-07-01), Platt et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 5801185 (1998-09-01), Platt et al.
patent: 6274597 (2001-08-01), Fan et al.
patent: 6291657 (2001-09-01), Platt et al.
patent: 6465488 (2002-10-01), Butters et al.
patent: 6583158 (2003-06-01), Fan et al.
patent: 6589964 (2003-07-01), Fan et al.
patent: 6599919 (2003-07-01), Fan et al.
patent: 6774135 (2004-08-01), Fan et al.
patent: 6916829 (2005-07-01), Fan et al.
patent: WO 87/03903 (1987-07-01), None
patent: WO 92/00277 (1993-04-01), None
patent: WO 99/40435 (1999-08-01), None
patent: WO 00/32175 (2000-06-01), None
patent: WO 00/33843 (2000-06-01), None
patent: WO 01/02862 (2001-01-01), None
patent: WO 01/21652 (2001-03-01), None
patent: WO 94/26714 (2001-09-01), None
patent: WO 02/28348 (2002-04-01), None
Zhou et al., ACorrection of defective protein trafficking of a mutant HERG potassium channel in human Long QT syndrome,@ J. Biol. Chem. 1999; 274(44):31123-31126.
Jian-Qiang Fan, et al., “Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor,” Nature Medicine 1999; vol. 5, No. 1, pp. 112-115.
Naoki Asano, et al., “In Vitro inhibition and intracelluar enhancement of lysosmal α-galactosidase A by deoxygalactonojirimycin and its derivatives,” Eur. J. Biochem 2000; vol. 267, pp. 4179-4186.
Tip W. Loo, et al., “Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators,” J. Biol. Chem. 1997; vol. 272, No. 2, pp. 709-712.
Barbara A. Foster, et al., “Pharmacological Rescue of mutant p53 conformation and function,” Science 1999; vol. 286, pp. 2507-2510.
Hideki Sakahira, et al., “Specific chaperone-like activity of inhibitor of caspase-activated DNase for caspase-activated DNase,” J. Biol. Chem. 2000; vol. 275, No. 11, pp. 8091-8096.
Jean-Pierre Morello, et al., “Pharmacological chaperones rescue cell-surface expression and functions of misfolded V2 vasopressin receptor mutants,” J. Clin. Invest. 2000; vol. 105, pp. 887-895.
C. Randall Brown, et al., “Chemical chaperones correct the mutant phenotype of the F508 cystic fibrosis transmembrane conductance regulator protein,” Cell Stress & Chaperones 1996; vol. 1, No. 2, pp. 117-125.
Ronald C. Rubenstein, et al., “Invitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylgutyrate in cystic fibrosis epithelial cells containing F508-CFTR,” Pharmacologic Correction of F508-CFTR 1997; vol. 100, No. 10, pp. 2457-2464.
Jon A. Bu{overscore (r)}ows et al., “Chemical chaperones mediate increased secretion fo mutant α1-antitrypsin (α 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency,” Proc. Natl. Acad. Sci. U.S.A. 2000; vol. 97, No. 4, pp. 1796-1801.
Galina Kuznetsov, et al., “Folding of secretory and membrane proteins,” New Engl. J. Med. 1998; vol. 339, No. 23, pp. 1688-1695.
Sue Wicker, et al., “Posttranslational quality control: folding, refolding, and degrading proteins,” Science 1999; vol. 286, pp. 1888-1893.
Jean-Pierre Morello, et al., “Pharmacological chaperones: a new twist on receptor folding,” TiPS, 2000; vol. 21, pp. 466-469.
F.M. Platt et al., “Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin,” Science 1997; vol. 276, pp. 428-431.
T. Okumiya et al., “Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease,” Biochem. Biophys. Res. Comm. 1997; vol. 214, pp. 1219-1224.
Naoki Ansano et al., “Homojirimycin iomers and glycosides fromAglaonema treubii,” J. Nat. Prod. 1997; vol. 60, p. 98.
A. M Hurtley and A. Helenius, “Protein oligomerization in the endoplasmic reticulum,” Annu. Rev. Cell Biol. 1989; vol. 5, pp. 277-307.
M.P. Dale et al., “Reversible inhibitors of beta-glucosidase,” Biochemistry 1985; vol. 24, pp. 3530-3539.
Frances M. Platt, et al., “N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis,” J. Biol. Chem. 1994; vol. 269, No. 11, pp. 8362-8365.
Frances M. Platt et al., “N-butuyldeoxygalactonorjirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing,” J. Biol. Chem. 1994; vol. 269, No. 43, pp. 27108-27114.
Ulla E. Petaja-Repo et al., “Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation,” The EMBO J. 2002; 21(7):1628-37.
Pobojewski et al., “Experimental drug reverses effects of Fabry disease,” The University Record (Univ. of Michigan), vol. 55, No. 34, p. 11, Jun. 2000.
Asano et al., “Specific alpha galactosidase inhibitors, N-methylcalystegines-structure/activity relationships of calystegines from Lycium chinense,” Eur. J. Biochem., vol. 248: 296-303, 1997.
Bernotas et al., “Sythesis of (+)-1, 5-dideoxy-1,5-imino-D-galactitol, a potent alpha galactosidase inhibitor,” Carbohydrate Res., vol. 167: 306-311, Sep. 1987.
Goldmann et al., “Biological activities of the nortropane alkaloid, calystegine B2, and analogs: structure function relationships,” J. Natl. Prod., vol. 59, pp. 1137-1142, 1996.
Legler et al., “Synthesis of 5-amino-5-deoxy-D-galactopyranose and 1,5-dideoxy-1,5-imino-D-galactitol, and their inhibition of alpha and beta-D-galactosidases,” Carbohydrate Research, vol. 155, pp. 119-129, Nov. 1986.
Naoki Ansano et al., “Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases,” J. Med. Chem. 1994; vol. 37, pp. 3701.
Ishii et al., “Characterization of a mutant α-galactosidase gene product for the late-onset cardiac form of Fabry disease,” Biochem. Biophys. Res. Comm. 1993; 197(3):1585-89.
Okumiya et al., Genetic Disease 1998; 2(1):76-82 (Japanese).
Asano Naoki
Fan Jian-Qiang
Ishii Satoshi
Baker & Botts LLP
Jiang Shaojia Anna
Khare Devesh
Mount Sinai School of New York University
LandOfFree
Method for enhancing mutant enzyme activities in Gaucher... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for enhancing mutant enzyme activities in Gaucher..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enhancing mutant enzyme activities in Gaucher... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3632492